Genomenon Announces Free Mastermind Genomic Search Engine
ANN ARBOR, Mich., Oct. 16, 2017 /PRNewswire-iReach/ -- Genomenon has announced that it will begin offering a free edition of the Mastermind Genomic Search Engine to clinical, research and academic institutions to advance genomic analysis and DNA data interpretation. Genomenon is making Mastermind freely available to promote more rapid advances in genome analysis and DNA sequencing interpretation.
Mastermind is the first-in-kind genomic search engine that connects clinicians and researchers directly to the most impactful scientific literature in their field. It provides a web-based search on a full complement of medical literature comprising over 5.5 million full text genomic articles cataloguing the genetic relationships to human diseases including cancer. With a simple query, Mastermind returns a list of prioritized, clinically relevant genomic articles including insight into gene, mutation and keyword matches for each article.
"Genomic interpretation is the most expensive, time consuming part of using Next Generation Sequencing (NGS) to analyze a patient's DNA. It takes highly trained professionals many hours to scour the literature for mutations that aren't well characterized in their databases," said Mike Klein, CEO of Genomenon. "Mastermind cuts the time and expense by getting interpretation specialists to the preeminent scientific literature that applies directly to their patient."
Genome interpretation in most labs relies heavily on PubMed, and Google Scholar. PubMed, an NIH database of medical literature citations, limits searches to titles and abstracts. It does not index entire documents and misses a vast majority of articles relevant to genomic interpretation. Google Scholar indexes over 100 million documents from a broad range of scientific and legal fields. However, it does not focus search results around genetic causes of human disease and it often returns and overwhelming list of search results, many of which are not clinically relevant.
Built with the express purpose of accelerating genome interpretation, Mastermind offers an alternative to PubMed and Google by delivering comprehensive, prioritized, clinically relevant search results with deep insight into the genomic literature. This helps clinicians and researchers find the most impactful scientific literature faster so they can focus only on articles that are relevant to their patients or research.
Genomenon will continue to offer a Professional Edition of Mastermind with enhanced data and clinical capabilities, Mastermind data access tools for workflow automation and analyzing large sets of genomic data, and professional genomic data analysis services such as its Evidence-Based Panel Design service.
Mastermind Free Edition is initially available by invitation only as the company scales its infrastructure to support a quickly growing user base. Interested genetic professionals and academic researchers can contact the company through its website http://www.genomenon.com to request an invitation. Over time, Genomenon plans to remove the invitation only restriction to make Mastermind available to a wider audience.
About Genomenon:
Genomenon is helping doctors, clinicians and researchers make sense of patients' DNA data. With the world's only comprehensive genomic-specific search engine, Genomenon helps doctors connect diseases and DNA profiles to the most impactful scientific genomic research to diagnose and treat patients. Our web-based search engine has indexed millions of medical articles cataloguing the genetic relationships between DNA and human diseases including cancer. Genomenon's solutions lower the cost of genetic tests, deliver faster diagnosis and help assure that no data is missed that can save a patient's life.
For more information, visit http://www.genomenon.com or email [email protected].
Media Contact: Jessica Francis, Genomenon, 4408404987, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Genomenon
iReach LastName, iReachCompany, 111-222-3333, [email protected]
Share this article